Curis 관리

관리 기준 확인 3/4

Curis CEO는 Jim Dentzer, Sep2018 에 임명되었습니다 의 임기는 6.25 년입니다. 총 연간 보상은 $ 1.66M, 38.1% 로 구성됩니다. 38.1% 급여 및 61.9% 보너스(회사 주식 및 옵션 포함). 는 € 18.01K 가치에 해당하는 회사 주식의 0.072% 직접 소유합니다. 18.01K. 경영진과 이사회의 평균 재임 기간은 각각 5.3 년과 10.4 년입니다.

주요 정보

Jim Dentzer

최고 경영자

US$1.7m

총 보상

CEO 급여 비율	38.1%
CEO 임기	6.3yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	5.3yrs
이사회 평균 재임 기간	10.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jim Dentzer 의 보수는 Curis 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$45m
Jun 30 2024	n/a	n/a	-US$48m
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$2m	US$634k	-US$47m
Sep 30 2023	n/a	n/a	-US$47m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$3m	US$615k	-US$57m
Sep 30 2022	n/a	n/a	-US$59m
Jun 30 2022	n/a	n/a	-US$57m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$3m	US$590k	-US$45m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$2m	US$545k	-US$30m
Sep 30 2020	n/a	n/a	-US$31m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$2m	US$510k	-US$32m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	n/a	n/a	-US$30m
Mar 31 2019	n/a	n/a	-US$32m
Dec 31 2018	US$2m	US$479k	-US$33m
Sep 30 2018	n/a	n/a	-US$35m
Jun 30 2018	n/a	n/a	-US$43m
Mar 31 2018	n/a	n/a	-US$48m
Dec 31 2017	US$2m	US$443k	-US$53m

보상 대 시장: Jim 의 총 보상 ($USD 1.66M )은 German 시장( $USD 468.04K ).

보상과 수익: Jim 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jim Dentzer (57 yo)

6.3yrs

테뉴어

US$1,662,978

보상

Mr. James E. Dentzer, also known as Jim, serves as Independent Director of Imunon, Inc. since September 2022. He serves as President, Chief Executive Officer & Director since September 24, 2018 and Secreta...

리더십 팀

이름	위치	테뉴어	보상	소유권
James Dentzer	President	6.3yrs	US$1.66m	0.072% € 18.0k
Diantha Duvall	CFO and Principal Financial & Accounting Officer	2.3yrs	US$1.01m	0.0076% € 1.9k
Jonathan Zung	Chief Development Officer	1.6yrs	US$1.04m	0% € 0
Mark Noel	Vice President of Technology Management & Intellectual Property	16.3yrs	US$413.39k	데이터 없음
Robert Martell	Chief Scientific Officer	no data	US$1.17m	데이터 없음
Elif McDonald	VP of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Reinhard von Roemeling	Senior Vice President of Clinical Development	5.3yrs	데이터 없음	데이터 없음

5.3yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: CUS0 의 관리팀은 노련하고 경험 (평균 재직 기간 5.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
James Dentzer	President	6.3yrs	US$1.66m	0.072% € 18.0k
Martyn Greenacre	Independent Chairman of the Board	24.8yrs	US$158.70k	0.015% € 3.9k
Marc Rubin	Independent Director	14.5yrs	US$123.70k	0.017% € 4.3k
Kenneth Kaitin	Independent Director	21.1yrs	US$126.20k	0.017% € 4.2k
John Hohneker	Independent Director	3yrs	US$106.20k	0% € 0
Anne Borgman-Hagey	Independent Director	2.2yrs	US$103.70k	0% € 0

10.4yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: CUS0 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.4 년).

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 17:46
장 마감 주가	2024/12/23 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Curis, Inc. 27 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Brian Skorney	Baird
James Birchenough	BMO Capital Markets Equity Research
Brian Skorney	Brean Capital

Curis 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc., Annual General Meeting, May 26, 2022

Recent updates

Curis, Inc. Announces Additional Data from Take Aim Leukemia Study

Third quarter 2024 earnings released: US$1.70 loss per share (vs US$2.13 loss in 3Q 2023)

Curis, Inc. to Report Q3, 2024 Results on Nov 14, 2024

New minor risk - Shareholder dilution

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million.

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million.

Second quarter 2024 earnings released: US$2.03 loss per share (vs US$2.47 loss in 2Q 2023)

Curis, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Curis, Inc. Announces Additional Data from Take Aim Leukemia Study

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$2.05 loss per share (vs US$2.39 loss in 1Q 2023)

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Curis, Inc., Annual General Meeting, May 21, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$8.96 loss per share (vs US$12.14 loss in FY 2022)

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2022)

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$0.61 loss per share (vs US$0.50 loss in FY 2021)

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.12 loss in 3Q 2021)

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.12 loss in 2Q 2021)

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021)

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2020)

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.28 loss in 1Q 2020)

Curis Receives U.S. Food and Drug Administration Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS

Full year 2020 earnings released: US$0.61 loss per share (vs US$0.97 loss in FY 2019)

Curis, Inc. to Report Q4, 2020 Results on Mar 16, 2021

Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Curis Announces Initiation of Investigator-Sponsored Phase 2 Lucas Study of Ca-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes

New 90-day high: €7.25

New 90-day high: €6.70

Curis, Inc. has completed a Follow-on Equity Offering in the amount of $147.500001 million.

Curis, Inc. Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

New 90-day high: €1.17

Third quarter 2020 earnings released: US$0.11 loss per share

Curis, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Curi Announces Appointment of Jason Sandner as its Next Chief Executive Officer, Effective July 1, 2021

Curis, Inc. Announces Abstract for CI-8993 Accepted for Presentation At the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting

New 90-day low - €0.74

First half earnings released

Curis, Inc. has completed a Follow-on Equity Offering in the amount of $17.5 million.